Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philipp Erben

Showing results (81-90 of 127) with videos related to

Pageof 13
Sort By:
Annals of Hematology|September 27, 2012
Activating CBL mutations are associated with a distinct MDS/MPN phenotypeJuliana Schwaab, Thomas Ernst, Philipp Erben, et al.
International Journal of Radiation Oncology, Biology, Physics|November 26, 2008
mRNA expression of platelet-derived growth factor receptor-beta and C-KIT: correlation with pathologic response to cetuximab-based chemoradiotherapy in patients with rectal cancerPhilipp Erben, Karoline Horisberger, Benjamin Muessle, et al.
European Urology Open Science|June 16, 2025
Clinical and Genomic Landscape of <i>FGFR3</i> Alterations Across Different Stages of Urothelial CancerMaximilian Haas, Roman Mayr, Danijel Sikic, et al.
Journal of Cancer Research and Clinical Oncology|June 23, 2014
Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phaseMichael Lauseker, Benjamin Hanfstein, Claudia Haferlach, et al.
Blood|September 26, 2009
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutationsMartin C Müller, Jorge E Cortes, Dong-Wook Kim, et al.
Genes, Chromosomes & Cancer|July 18, 2006
Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion geneChristoph Walz, Claire Curtis, Susanne Schnittger, et al.
Journal of Personalized Medicine|June 2, 2021
KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder CancerHendrik Jütte, Moritz Reike, Ralph M Wirtz, et al.
European Urology|March 30, 2022
Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin ImmunotherapyRoman Mayr, Markus Eckstein, Ralph M Wirtz, et al.
Blood|June 28, 2011
Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3Christoph Walz, Philipp Erben, Michael Ritter, et al.
International Journal of Radiation Oncology, Biology, Physics|January 10, 2009
Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trialKaroline Horisberger, Anne Treschl, Sabine Mai, et al.
Pageof 13

Showing results (81-90 of 127) with videos related to

Sort By:
Pageof 13
Annals of Hematology|September 27, 2012
Activating CBL mutations are associated with a distinct MDS/MPN phenotypeJuliana Schwaab, Thomas Ernst, Philipp Erben, et al.
International Journal of Radiation Oncology, Biology, Physics|November 26, 2008
mRNA expression of platelet-derived growth factor receptor-beta and C-KIT: correlation with pathologic response to cetuximab-based chemoradiotherapy in patients with rectal cancerPhilipp Erben, Karoline Horisberger, Benjamin Muessle, et al.
European Urology Open Science|June 16, 2025
Clinical and Genomic Landscape of <i>FGFR3</i> Alterations Across Different Stages of Urothelial CancerMaximilian Haas, Roman Mayr, Danijel Sikic, et al.
Journal of Cancer Research and Clinical Oncology|June 23, 2014
Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phaseMichael Lauseker, Benjamin Hanfstein, Claudia Haferlach, et al.
Blood|September 26, 2009
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutationsMartin C Müller, Jorge E Cortes, Dong-Wook Kim, et al.
Genes, Chromosomes & Cancer|July 18, 2006
Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion geneChristoph Walz, Claire Curtis, Susanne Schnittger, et al.
Journal of Personalized Medicine|June 2, 2021
KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder CancerHendrik Jütte, Moritz Reike, Ralph M Wirtz, et al.
European Urology|March 30, 2022
Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin ImmunotherapyRoman Mayr, Markus Eckstein, Ralph M Wirtz, et al.
Blood|June 28, 2011
Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3Christoph Walz, Philipp Erben, Michael Ritter, et al.
International Journal of Radiation Oncology, Biology, Physics|January 10, 2009
Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trialKaroline Horisberger, Anne Treschl, Sabine Mai, et al.
Pageof 13